A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection
- Conditions
- Covid19
- Registration Number
- NCT04725097
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The purpose of this study is to assess the ability of an artificial intelligence smartphone-enabled point of care ECG to detect COVID-19.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2821
- Adult males and females age 18 or greater.
- Undergoing COVID-19 testing by PCR.
- Willing and able to provide informed consent.
- Pregnant females (minimal risk study, no risk from ECG).
- Unwilling or unable to provide informed consent.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method COVID 19 Detection One time screening within 4 hours of PCR test Determine the safety and feasibility of the POC AI-ECG's ability to detect active SARS-Cov-2 infection in humans.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (8)
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
LSUHSC Shreveport
🇺🇸Shreveport, Louisiana, United States
Henry Ford Health System
🇺🇸West Bloomfield, Michigan, United States
Hackensack Meridian Health
🇺🇸Hackensack, New Jersey, United States
Sri Jayadeva
🇮🇳Bengaluru, Karnataka, India
King Edward Memorial Hospital
🇮🇳Mumbai, Maharashtra, India
Gregorio Marañon Hospital
🇪🇸Madrid, Spain
Imperial College
🇬🇧London, England, United Kingdom
Mayo Clinic🇺🇸Rochester, Minnesota, United States